Federico Gardini
Corporate Officer/Principal en Bio3 Research SRL .
Cargos activos de Federico Gardini
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Bio3 Research SRL
Bio3 Research SRL Medical SpecialtiesHealth Technology Bio3 Research SRL is engaged in the research, identification and development of novel therapeutic agents, specializing in the biotechnology, bioelectronics, and biomedicine fields. The firm develops proprietary compounds that serve as inhibitors in diseases related to High Mobility Group Box 1 (HMGB1) protein over-expression and biological properties. It monitors the effect of developed and patented biological agents on cardiovascular disorders, renal disorders, and connective tissue regeneration, such as cartilage repair, wound healing, and bone matrix regeneration. It collaborates with biopharmaceutical companies, academies, and scientists, with focus on intellectual property transfer, patent registration, and commercialization of novel products in the pharmaceutical marketplace. The company was founded by Francesco Paolo Pilato in 2001 and is headquartered in Milan, Italy. | Corporate Officer/Principal | - | - |
Historial de carrera de Federico Gardini
Antiguos cargos conocidos de Federico Gardini.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Bio3 Research, Inc. | Director de Operaciones | - | - |
Formación de Federico Gardini.
University of Bocconi | Undergraduate Degree |
Estadísticas
Internacional
Italia | 3 |
Estados Unidos | 2 |
Operativa
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Chief Operating Officer | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Bio3 Research SRL
Bio3 Research SRL Medical SpecialtiesHealth Technology Bio3 Research SRL is engaged in the research, identification and development of novel therapeutic agents, specializing in the biotechnology, bioelectronics, and biomedicine fields. The firm develops proprietary compounds that serve as inhibitors in diseases related to High Mobility Group Box 1 (HMGB1) protein over-expression and biological properties. It monitors the effect of developed and patented biological agents on cardiovascular disorders, renal disorders, and connective tissue regeneration, such as cartilage repair, wound healing, and bone matrix regeneration. It collaborates with biopharmaceutical companies, academies, and scientists, with focus on intellectual property transfer, patent registration, and commercialization of novel products in the pharmaceutical marketplace. The company was founded by Francesco Paolo Pilato in 2001 and is headquartered in Milan, Italy. | Health Technology |
Bio3 Research, Inc. |
- Bolsa de valores
- Insiders
- Federico Gardini
- Experiencia